{"entity":{"id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab and PM8002 in advanced solid tumours, run by DualityBio Inc., active and no longer recruiting.","summary":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05438329 by DualityBio Inc., with 1123 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2027-08-13. Interventions recorded: DB-1305/BNT325, Pembrolizumab and BNT327.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05438329","url":"https://clinicaltrials.gov/study/NCT05438329"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","pm8002"],"companies":["dualitybio","biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05438329","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","enrolled":1123,"outcomes":[]},"route":"/trials/nct05438329/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}